杭州新诺华医药

Hangzhou Xinnuohua Pharmaceutical Co., Ltd. is a pharmaceutical research and development company based in Hangzhou, China, and a wholly-owned subsidiary of Ningbo Menovo Pharmaceutical Co., Ltd. Founded in 2012, the company serves as the core formulation R&D center for the Menovo group, specializing in the development of high-barrier generic drugs and complex oral solid dosage forms. Its technical capabilities are built around several advanced platforms, including sustained-release and controlled-release technologies, pellet formulations, and solubilization techniques. The company's portfolio focuses on therapeutic areas such as cardiovascular diseases, central nervous system disorders, and metabolic conditions, with a pipeline that includes both commercialized generics and innovative projects like JH389 for weight management. Hangzhou Xinnuohua plays a pivotal role in Menovo's API-Formulation Integration strategy, supporting the registration and global commercialization of high-quality pharmaceutical products.